Research & Development
JanOne implements manufacturing contract for formulation and manufacturing of TV1001SR
7 February 2020 -

It was reported on Thursday that JanOne Inc (NASDAQ: JAN), a pharmaceutical company focused on pain reduction treatments, has begun a contract to manufacture TV1001SR, a treatment for Peripheral Artery Disease.

The product aims to address the underlying cause of Peripheral Artery Disease and associated pain, as a potential alternative to opioids.

Tony Giordano, PhD, JanOne's chief scientific officer, said, 'CoreRx's extensive clinical development experience and capabilities made them a natural choice for phase 2b formulation and manufacturing. As we finalize our clinical protocols for FDA submission and enter the next phase of trials for what we believe could be an effective PAD treatment, CoreRx is a proven partner with exceptional quality controls.'



Related Headlines